2nd Nottingham IBD Masterclass, 2017
|
|
- Jordan Dickerson
- 5 years ago
- Views:
Transcription
1 2nd Nottingham IBD Masterclass, 217 Positioning IL12/IL23 blockade in the Crohn s disease treatment algorithm Prof James Lindsay, Consultant Gastroenterologist, Barts Health NHS Trust Professor in Inflammatory Bowel Disease Barts and The London School of Medicine Queen Mary University of London
2 Speaker Declarations This presenter has the following declarations of relationship with industry Served as consultant and an advisory board participant for AbbVie, Actavis (Warner Chilcott), Atlantic Healthcare, Celtrion, Ferring, Jansen, MSD, Napp, Pfizer, Shire, Takeda and Vifor Pharma Received speaker fees and sponsorship to attend academic meetings from AbbVie, Actavis (Warner Chilcott), Ferring, MSD, Shire and Tillott s and Takeda Received investigator led research grants from Hospira, Shire and Takeda [November 217]
3 Managing Crohn s disease in 217 Our therapeutic choices are increasing Tumour necrosis factor antagonists (anti-tnfs) Initial report 5ASA, Steroids, Azathioprine Methotrexate, ciclosporin Vedolizumab Biosimilars Ustekinumab Rizankizumab Surgery With choice comes responsibility. Choose correct drug at the correct time Monitor patient to ensure response Modify therapy as appropriate Reflection...
4 Positioning IL12/IL23 blockade in Crohn s disease What I am aiming to cover Why do we need new drugs for Crohn s disease Introducing the IL-12 / IL-23 pathway Clinical data supporting efficacy of drugs that target this pathway Practical questions for ustekinumab.
5 Why do we need new therapies? Treatment goals have changed to improve outcome Symptomatic benefit Steroid-free remission Mucosal healing Histological remission Prevent hospitalisation and surgery Early Induce disease remission (B1) Later Maintain disease remission (B2 / B3) Prevent Post complications surgery end Enhance stage QOL disease
6 Percentage of patients Why do we need new therapies? Optimal use of current therapies does not work in all patients anti TNF using treat to target approach in Crohn s disease: CALM 1 1 o Endpoint: mucosal healing (CDEIS <4) and no deep ulcerations 8 p=.1 Therapeutic Gap /122 56/122 Clinical management Tight control Endoscopic scoring is based on site read. Cochran-Mantel-Haenszel test stratified by smoking status (yes/no) and weight (<7/ 7 kg) at screening. NRI analysis. CDEIS: Crohn s disease endoscopic index of severity; NRI: non-responder imputation. Colombel JF, et al. Gastroenterology 217;152(Suppl 1):S155; Colombel JF, et al. Lancet
7 Why do we need new therapies? Current therapies do not work in all: secondary loss of response PANTS data courtesy G Heap and T Ahmad
8 Why do we need new therapies? Some patients develop adverse reactions to current therapies Distribution of skin lesion in the 29% of patients 264/917 (29%) patients treated with anti-tnf developed skin lesions In 28/264 patients (11%) skin lesions were a reason to stop therapy 3.8% 5.3% 26.2% 3.6% 1.6% 23.5% Psoriasiform eczema Eczema Xerosis cutis Palmoplantar pustulosis Psoriasis Other Cleynen I, et al. Ann Intern Med. 216;164:1-22.
9 Remission at weeks 4-8 (%) Remission at weeks (%) Why do we need new therapies? Switching drugs in class are less effective in non responders 1 Efficacy of adalimumab after failure of infliximab in Crohn s: Meta analysis Primary N/R Secondary N/R Intolerance Primary N/R Secondary N/R Intolerance Gisbert JP, et al. Aliment Pharmacol Ther. 215;41:613-23
10 Patients, % Patients, % Why do we need new therapies? Switching drugs out of class is less effective. GEMINI II: Vedolizumab is less effective in anti TNF refractory Crohn s disease Induction of Remission Week 6 Anti-TNF naïve/failure: 5/5 Maintenance of Remission Week 52 1 Patients With Anti- TNFα Failure (n=175) Patients Without Anti-TNFα Failure (n=193) 1 Patients With Prior Anti- TNFα Failure (n=237) Patients Without Prior Anti- TNFα Failure (n=224) PBO VDZ VDZ/PBO VDZ Q8W VDZ Q4W Clinical Remission CDAI-1 Response Clinical Remission CDAI-1 Response Clinical Remission CDAI-1 Response Clinical Remission CDAI-1 Response Adapted from: Sands BE et al. Presentation at: UEGW 2th Annual Meeting 212.
11 Positioning IL12/IL23 blockade in Crohn s disease What I am aiming to cover Why do we need new drugs for Crohn s disease Anti TNF therapies are effective and induce mucosa healing Even with treat to target approach 5% have active disease Progressive loss of response due to ADA formation Second line anti TNFs are less effective Vedolizumab less effective in anti TNF exposed.
12 Y Introducing the IL-12 / IL23 pathway A role in IBD pathogenesis. Lumen DC TLR IFN-g, TNF-a, MMP Lamina propria apoptosis APC IL-1 Th1 YYTh1/17 Treg TGF-b Th1 Treg Chemokines Th1/17 Endothelium DC T cell Th17 IL-12, IL-23 Th1 Mesenteric LN adhesion molecules
13 Introducing the IL-12 / IL23 pathway Two new drugs for Crohn s disease Anti P4 Ustekinumab : Phase III induction and maintenance in CD Anti P19 Risankizumab: Phase II induction in CD Ustekinumab
14 Ustekinumab for Crohn s disease Phase III clinical trial data: Uniti UNITI-1: TNF-α failure population R Placebo IV (N=247) UST 13 mg IV (N=245) IM-UNITI 44-week randomised withdrawal maintenance study IM-UNITI LTE Up to 4-year study extension UST ~6 mg/kg IV (N=249) UNITI-2: Failed conventional therapy R Placebo IV (N=29) UST 13 mg IV (N=21) UST ~6 mg/kg IV (N=29) Responders 9 mg SC q8 wks (N=132) R 9 mg SC q12 wks (N=132) Placebo SC (N=133) Responders 75% (298/397) of randomised subjects who started maintenance entered LTE 56% (718/1281) of all subjects who started maintenance continued in LTE IV, intravenous; LTE, long-term extension; SC, subcutaneous; TNF-α, tumor necrosis factor α; UST, ustekinumab Feagan BG, et al. N Engl J Med. 216;375:
15 Patients (%) Patients (%) Ustekinumab for Crohn s disease Phase III clinical trial data: induction data 1 Clinical response (a decrease of 1 points from BL in CDAI score or a CDAI score < 15 points) a UNITI-1 TNF antagonist failure Primary endpoint 1 UNITI-2 failed conventional Primary endpoint 8 p =.1 p =.3 8 p <.1 p =.1 p <.1 p <.1 6 p =.49 p = Week 3 Week 6 Week 3 Week 6 Placebo UST 13 mg UST ~6 mg/kg a ITT, 2-sided Cochran-Mantel-Haenszel chi-square test at a significance level of.5. BL, baseline; CDAI, Crohn s Disease Activity Index. Feagan BG, et al. N Engl J Med. 216;375:
16 Daily score change (mean) Ustekinumab for Crohn s disease Phase III clinical trial data: induction data Early symptomatic improvement in PRO Mean change of soft/liquid stools from baseline (number per day) Mean change of abdominal pain from baseline (rated 3) Mean change of general wellbeing from baseline (rated 4) Time (days) Time (days) Time (days) * * * ** ** * * * ** ** * ** ** * ** ** * * ** * * * * ** ** ** ** ** ** ** * * * * * ** ** ** ** ** 1.4 * ** ** **.6.6 PBO (n = 191) UST 13 mg (n = 188) UST ~6 mg/kg (n = 184) * p <.5 for UST 13 mg vs placebo. ** p <.5 for UST ~6 mg/kg vs placebo. PBO, placebo. Adapted from Sandborn WJ, et al. Presented at ACG 217; P2145.
17 Patients (%) Ustekinumab for Crohn s disease Phase III clinical trial data: maintenance data Primary and major secondary endpoints in IM-UNITI at Week Placebo UST 9 mg q12w UST 9 mg q8w p =.2 p =.7 p =.5 p =.3 p =.19 p = p =.4 p = n = Clinical remission Clinical response Remission among those in remission at IM-UNITI week Glucocorticoid -free remission Feagan BG, et al. N Engl J Med. 216;375:
18 Patients (%) Ustekinumab for Crohn s disease Phase III clinical trial data: maintenance data Remission in UNITI-1 and UNITI-2 subgroups in IM-UNITI Placebo UST 9 mg q12w UST 9 mg q8w p =.1 p =.14 p =.2 p = n = UNITI-1 population (TNF antagonist failure) UNITI-2 population (failed conventional) Feagan BG, et al. N Engl J Med. 216;375:
19 Mean SES- CD Reduction (from Induction Baseline) Proportion of Subjects Ustekinumab for Crohn s disease Phase III clinical trial data: Endoscopic data at week (P=.54) 3.8 5% 4% 21.1% (P=.17) 48.6% 2.1% P=.12 Placebo (n=51) UST q12w (n=47) UST q8wk (n=74) (P=.758) 1.5 3% 2% 29.8% 27.5% 17.% 33.8% 11.8% P= % % 13.7% 9.8% 12.8%. Placebo (n=51) UST q12w (n=47) Improvement in SES-CD *Subjects with eligible SES-CD and ulcerations at baseline UST q8w (n=74) % SES-CD 3-pt Reduction Endoscopic Response Mucosal Healing Endoscopic Response (5% SES-CD improvement) Endoscopic Remission (SES-CD <2) Rutgeerts P, et al. UEGW 216. Presentation 14.
20 Ustekinumab for Crohn s disease Phase III clinical trial data: safety data Treated subjects who were randomized (n) Avg. duration of follow-up (weeks) Ustekinumab Placebo SC* 9 mg SC q12w 9 mg SC q8w Combined Subjects with (%) Death % % % % AEs 83.5% 8.3% 81.7% 81.% SAEs 15.% 12.1% 9.9% 11.% Infections 49.6% 46.2% 48.1% 47.1% Serious infections 2.3% 5.3% 2.3% 3.8% Discontinuation due to AE 6.% 7.6% 3.1% 5.3% Malignancies.8% %.8% % MACE % % % % *Subjects 2 who were in clinical response to ustekinumab IV induction dosing and were randomized to placebo SC on entry to this maintenance study Malignancies 2 were both Basal cell skin cancers, 1 each in the Placebo and q8w groups Sandborn W.J., et al. DDW 216. Presentation 768.
21 Subject in clinical remission (%) Ustekinumab for Crohn s disease Phase III clinical trial data: Uniti long term extension Clinical remission was well maintained over time No new safety signals identified in LTE ITT analysis % 77.4% 74.4% 72.6% 4 2 UST 9 mg q12w (n = 84) UST 9 mg q8w (n = 82) ITT, intent-to-treat population. Time (weeks) Sandborn WJ, et al. Poster presented at ECCO 217; #OP1.
22 New therapies in IBD: what does the future hold? Drugs that IL-23 signalling: anti P19 Risankizumab Anti P4 Ustekinumab : Phase III induction and maintenance in CD Anti P19 Risankizumab: Phase II induction and OLE in CD Ustekinumab
23 Randomised 1:1:1 Drugs that target IL-23: what does the future hold? anti P19 Risankizumab phase II data Period 1 Blinded iv therapy Period 2 Open label iv therapy/washout N=41 Risankizumab 6 mg iv q4w No Risankizumab 6 mg iv q4w N=41 Risankizumab 2 mg iv q4w Week 12 Deep remission? Period 3 Open label sc therapy N=39 Placebo iv Yes Flare* Wash out Dosing Day 1 Wk 12 Primary endpoint: Clinical remission at Week 12 Wk 14 Wk 26 Clinical remission defined as a CDAI <15. Deep remission is defined as clinical remission and endoscopic remission (CDEIS of 4; for patients with isolated ileitis of CDEIS 2). *If CDEIS score >4 (or above 2 for patients with initial isolated ileitis), patients to receive open-label iv induction therapy (6 mg risankizumab x 3 q4w). ClinicalTrials.gov identifier, NCT CDAI, Crohn s Disease Activity Index; CDEIS, Crohn s Disease Endoscopic Index of Severity
24 Drugs that target IL-23: what does the future hold? anti P19 Risankizumab phase II data Methods: Phase 2, placebo-controlled, double-blind, 12-week induction trial (3 doses) Results: Endoscopies at baseline and at week 12 assessed by blinded central reader 94.2% were anti-tnf experienced; 56-59% had >2 prior anti-tnfs Week 12 Efficacy (primary endpoint): Clinical remission at week 12 Endoscopic response at week 12 Feagan BG, et al. Presented at DDW. May 216. Abstract 768. Endoscopic response > 5% fall in CDEIS
25 Proportion of patients (%) Drugs that target IL-23: what does the future hold? anti P19 Risankizumab phase II data Period 1 induction regimen Placebo Risankizumab 2 mg 6 mg Patients entering period Patients in deep remission entering wash out 1 5 Patients receiving 6 mg risankizumab Clinical remission 8 7 Week 12 (after randomised blinded therapy) Week 26 (after OL 6 mg risankizumab therapy or wash out) n/n 6/39 1/41 15/41 18/39 22/41 22/41 Week 12 Week 26 Placebo 2 mg Risankizumab 6 mg Risankizumab
26 Positioning IL12/IL23 blockade in Crohn s disease Practical questions for ustekinumab Does it work in the real world Should you persist if no response to IV dose Should I use it in combination with azathioprine Does it heal perianal disease Should I measure drug levels Is it safe outside of clinical trials?
27 Practical questions for ustekinumab Does it work in the real world? Retrospective Cohort Study 167 UST Treated CD Patients Primary outcome: clinical & objective response & remission at 3, 6 & 12 months Clinical response: HBI fall of 3 points, clinical remission: HBI 4 points Objective remission: improvement in endoscopic or radiographic (CT/MRE) Ma C, et al. Presented at DDW. May 217. Abstract Sa1967.
28 Proportion of Subjects (%) Practical questions for ustekinumab Should you persist if no response to iv dose? Delayed responders: clinical response and remission 8 weeks after first SC dose 1 Non-responders to 13mg or 6mg/kg IV 8 6 Response 5.5 N=467 Remission * Subjects who were in clinical response to ustekinumab IV induction dosing and were randomised to placebo SC on entry to this maintenance study ** Includes data up to Week 44 Note: Only maintenance Week 8 responders continued to receive UST (n=251) Subjects who had insufficient data to calculate the CDAI score at the designated analysis timepoint are considered not to be in clinical remission Sands BE, et al. UEGW 216. Presentation 5.
29 Patients in clinical remission (%) Practical questions for ustekinumab Should you persist if no response to iv dose? Clinical remission through Week 44: delayed responders group from induction 1 8 Randomized 9 mg SC q8w (N = 128) Non-responders to UST IV induction (given 9 mg SC q8w; N = 251) % 53.7% 53.4% 5.2% Time (weeks) Of 467 patients given induction treatment at week, 251 were in clinical response and continued to receive 9 mg SC q8w in the maintenance study These data provide clinical rationale for providing at least 1 SC maintenance dose of UST irrespective of clinical response 8 weeks after IV induction, as described in the EU SmPC SmPC, summary of product characteristics. Adapted from Colombel J-F, et al. Presented at ACG 217; P2133. Ustekinumab SmPC, EMA, date of implementation: October 217.
30 Proportion of Patients (%) Proportion of Patients (%) Practical questions for ustekinumab Does it heal perianal disease? Methods A combined post-hoc analysis of UNITI-1, UNITI-2 and CERTIFI Results 12.3% had active perianal fistula (161 patients) Fistula Resolution (1% Reduction) at Week 8 Among Randomized Patients with Open, Draining Fistulas at Baseline in Pooled Data from CERTIFI, UNITI-1 and UNITI Placebo P=.134 P=.52 P= /71 16/66 18/65 37/15 1 mg/kg and 13 mg 6 mg/kg and ~6 mg/kg Ustekinumab All UST Doses Combined Patients in Fistula Response ( 5% Reduction) in Primary Population Through Week 44 (52 Weeks Post-Induction) in IM-UNITI UST Induction Week 8 Clinical Responders with Open, Draining Fistulas at Baseline Randomized to SC Ustekinumab or Placebo in IM-UNITI at Each Visit Through Week n=21 n=21 n=21 n=13 n=13 n=13 Placebo SC n=2 n=13 n=17 n=17 n=13 n=13 n=17 n=13 Combined SC UST n=16* n=16* n=15* n=12 n=12 n=12 n=15* n=15 n=12 n= Weeks Post Maintenance *P<.5 Sands et al. Presented at DDW. May
31 Median serum UST concentration (μg/l) Practical questions for ustekinumab Should I use in combination with azathioprine? No difference in response rates in Phase III clinical trials Retrospective French cohort of 122 anti TNF refractory patients showed response of 65% at 3/12: IM at baseline increased OR of clinical response 5.45 (95%CI ; p=.3) Median serum UST concentrations in IM-UNITI UST 6 mg/kg IV (I) 9 mg SC q8w (M) Receiving AZA, 6-MP, or MTX Not receiving AZA, 6-MP, or MTX MP, 6-mercaptopurine; AZA, azathioprine; MTX, methotrexate. Adapted from Adedokun OJ, et al. Presented at ACG 217; P2163.
32 Practical questions for ustekinumab Should I measure drug levels? Simple answer currently not available! Clinical remission at week 24 Based on ROC analyses, trough concentrations of μg/ml or greater were associated clinical remission CRP normalisation at week 24
33 Number of TB Cases per 1 Patient-Years Practical questions for ustekinumab Is it safe? Lower Rates of Active TB with ustekinumab than anti-tnf Agents Compared safety data in Phase 2/3 trials for ustekinumab, infliximab and golimumab across all indications Active TB cases were significantly lower with ustekinumab compared to anti-tnf therapy (n=2, <.1% vs. n=58,.5%) Frequency (%) (Drug vs. Comparator) Ustekinumab (n=6,581) Anti-TNF (11,839) <.1 vs...5 vs. <.1 Active TB Cases 2 58 Exposure in Patient Years 12,122 2,538 Active TB cases per 1 patient-years % Confidence Intervals Active TB Cases Per 1 Patient-Years in the All Trial Populations (95% CI=.21,.37) (95% CI= 1..,.6) Anti-TNF All Trial Anti-IL12/23 All Trial 1,2 3 Population Population Exposure in Patient Years Loftus EV, et al. Presented at DDW. May 217. Abstract
34 Events per 1 patient-years Practical questions for ustekinumab Is it safe? 4 Cumulative incidence rates of serious infections of interest per 1 patient-years (PY) in PSOLAR registry Ustekinumab* Infliximab* Adalimumab* Cohort Overall population* Adapted from Kalb R et al Study limitations inherent to observational studies including treatment selection and patient participation biases due to the lack of randomisation. Limitations specific to the PSOLAR study include: some differences were noted in patient characteristics across biologic cohorts at entry into the registry; statistical significance may not necessarily connote clinical relevance. Error bars are representative of 95% CI. 1 All products have specific benefits and risks, please see each product's Summary of Product Characteristics for full details. *Data are shown by treatment cohort in the overall population. The overall population includes patients who received a biologic agent before (prevalent population) or after (incident population) enrolling in the registry Kalb R, et al. JAMA Dermatol. 215; 151:
35 Positioning IL12/IL23 blockade in Crohn s disease Factors that drive biologic treatment decisions Disease phenotype Disease activity / perianal disease / EIM Patient comorbidity Age / previous malignancy / risk of infection Previous treatment history Therapeutic drug monitoring with anti TNF agents Adverse events Cost biosimilar revolution Patient preference Route of administration
36 Positioning IL12/IL23 blockade in Crohn s disease Conclusions: IL-12/23 blockade is a third class of biologic therapy Ustekinumab is licensed for use in the UK Efficacy in anti TNF failures as well as naïve NICE approved for first and second line use Rizankizumab is in phase III trial development No head to head trials to compare efficacy Treatment decisions relate to patient factors / cost Increasing options should drive careful patient monitoring to allow therapy to be optimised
Predicting response to anti - integrin therapy: long term efficacy and roles for optimisation with vedolizumab.
Predicting response to anti - integrin therapy: long term efficacy and roles for optimisation with vedolizumab. Dr Peter Irving Guy s and St Thomas Hospital, London King s College London Response to vedolizumab
More informationΑπό τη θεωρία στη πράξη: Συζήτηση κλινικών περιστατικών. Κωνσταντίνος Κατσάνος Επίκουρος Καθηγητής Γαστρεντερολογίας Πανεπιστήμιο Ιωαννίνων
Από τη θεωρία στη πράξη: Συζήτηση κλινικών περιστατικών Κωνσταντίνος Κατσάνος Επίκουρος Καθηγητής Γαστρεντερολογίας Πανεπιστήμιο Ιωαννίνων Conflict of interest By means of this, the speaker confirms that
More informationSelection and use of the non-anti- TNF biological therapies: Who? When? How?
Selection and use of the non-anti- TNF biological therapies: Who? When? How? Asher Kornbluth, MD Clinical Professor of Medicine The Henry D. Janowitz Division of Gastroenterology The Icahn School of Medicine
More informationRecent Advances in the Management of Refractory IBD
Recent Advances in the Management of Refractory IBD Raina Shivashankar, M.D. Assistant Professor of Medicine Division of Gastroenterology and Hepatology Thomas Jefferson University Philadelphia, PA Outline
More informationUpdate on Biologics in Ulcerative Colitis. Scott Plevy, MD University of North Carolina Chapel Hill, NC
Update on Biologics in Ulcerative Colitis Scott Plevy, MD University of North Carolina Chapel Hill, NC Objectives Discuss the latest advances in the pharmacologic management of ulcerative colitis Describe
More informationSeptember 12, 2015 Millie D. Long MD, MPH, FACG
Update on Biologic Therapy in 2015 September 12, 2015 Millie D. Long MD, MPH, FACG Assistant Professor of Medicine Inflammatory Bowel Disease Center University of North Carolina-Chapel Hill Outline Crohn
More informationIBD Updates. Themes in IBD IBD management journey. New tools for therapeutic monitoring. First-line treatment in IBD
IBD Updates Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida Themes in IBD 213 First-line treatment in IBD New tools for therapeutic monitoring Biologic therapy for CD and
More informationDisclosures. What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists
What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists Disclosures No financial relationships to disclose. 1 Learning Objectives Case 24M with ileocolonic
More informationAn Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease. David A. Schwartz, MD
An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University
More informationU of Cape Town, South Africa, 10 U of Washington, Seattle, WA,USA, 11 CHRU de Lille, Hôpital Claude Huriez, Lille, France, 12
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Ustekinumab, a Human IL-12/23p40 Monoclonal Antibody, in Moderate-severe Crohn s Disease Refractory to Anti-TNFα: UNITI-1 WJ Sandborn 1,
More informationBiologics in IBD. Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College
Biologics in IBD Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College Case 30 year old man diagnosed with ulcerative proctitis diagnosed in 2003 Had been maintained
More informationNew treatment options in IBD: today and the future. Silvio Danese Istituto Clinico Humanitas, Milan, Italy
New treatment options in IBD: today and the future Silvio Danese Istituto Clinico Humanitas, Milan, Italy Date of preparation: October 2014 GLO/EYV/2014-00010h Overview of the late-stage IBD drug pipeline*
More informationNew treatment options in UC. Rob Bryant IBD Consultant Royal Adelaide Hospital
New treatment options in UC Rob Bryant IBD Consultant Royal Adelaide Hospital Talk Outline 1. Raising expectations 2. Optimising UC therapy 3. Clinical trials 4. What s new on the PBS? 5. Questions 1.
More informationMucosal healing: does it really matter?
Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does it really matter? Professor Jean-Frédéric Colombel, New York, USA Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does
More informationSYNOPSIS. Issue Date: 25 Oct 2011
SYNOPSIS Issue Date: 25 Oct 2011 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Janssen Research & Development STELARA Ustekinumab Protocol No.: Title of Study: Study Name:
More informationMedical Management of Inflammatory Bowel Disease
Medical Management of Inflammatory Bowel Disease John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University John K. Marshall: Conflicts of Interest Speaker: AbbVie, Allergan, Ferring,
More informationHighlights of DDW 2015: Crohn s disease
Highlights of DDW 2015: Crohn s disease Mark S. Silverberg, MD, PhD, FRCPC Associate Professor of Medicine, University of Toronto Staff Gastroenterologist, Mount Sinai Hospital Senior Investigator, Lunenfeld-Tanenbaum
More informationEmerging g therapies for IBD: A practical approach to positioning. Sequential Therapies for IBD
Emerging g therapies for IBD: A practical approach to positioning Stephen B. Hanauer, MD Sequential Therapies for IBD Disease Severity at Presentation Severe Anti-TNF +/IS Cyclosporine (UC) Colectomy (UC)
More informationBiologic Therapy for Ulcerative Colitis in 2015
5/6/215 Biologic Therapy for Ulcerative Colitis in 215 John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University Bressler B, Marshall JK, et al. Gastroenterology 215;148: 135-58
More informationSYNOPSIS. Approved Date: 9 November 2015 Prepared by: Status: Janssen Research & Development, LLC
SYNOPSIS Name of Sponsor/Company Janssen Research & Development* Name of Investigational Product STELARA (ustekinumab) * Janssen Research & Development is a global organization that operates through different
More informationIndications for use of Infliximab
Indications for use of Infliximab Moscow, June 10 th 2006 Prof. Dr. Dr. Gerhard Rogler Klinik und Poliklinik für Innere Medizin I Universität Regensburg Case report 1989: Diagnosis of Crohn s disease of
More informationMono or Combination Therapy with. Individualized Approach
Mono Combination Therapy with Biologics i in IBD: Developing an Individualized Approach David T. Rubin, MD, FACG Co-Direct, Inflammaty Bowel Disease Center Fellowship Program Direct University of Chicago
More informationAzathioprine for Induction and Maintenance of Remission in Crohn s Disease
Azathioprine for Induction and Maintenance of Remission in Crohn s Disease William J. Sandborn, MD Chief, Division of Gastroenterology Director, UCSD IBD Center Objectives Azathioprine as induction and
More informationChoosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball
Choosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball Siddharth Singh, MD, MS Assistant Professor of Medicine Division of Gastroenterology Division of Biomedical
More informationSevere IBD: What to Do When Anti- TNFs Don t Work?
Severe IBD: What to Do When Anti- TNFs Don t Work? David T. Rubin, MD, FACG Professor of Medicine Co-Director, Inflammatory Bowel Disease Center Interim Chief, Section of Gastroenterology, Hepatology and
More informationSTELARA (ustekinumab) Clinical Study Report CNTO1275CRD3001
SYNOPSIS Name of Sponsor/Company Janssen Research & Development* Name of Investigational Product STELARA (ustekinumab) * Janssen Research & Development is a global organization that operates through different
More informationGionata Fiorino VEDOLIZUMAB E IBD. Un nuovo target terapeutico
Gionata Fiorino VEDOLIZUMAB E IBD Un nuovo target terapeutico Anti cell adhesion molecules Danese S, NEJM 2011 6 Steps leukocyte recruitment Fiorino G. et al. 2010 Vedolizumab Blocks Fewer Biological Pathways
More informationMucosal Healing in Crohn s Disease. Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium
Mucosal Healing in Crohn s Disease Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium Mucosal Lesions in CD: General Features CD can affect the entire GI tract
More informationBiologic Therapy for Inflammatory. Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida
Biologic Therapy for Inflammatory Bowel Disease: Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida Learning Objectives Evaluate evidence
More informationNew and Future Adhesion Molecule Based Therapies in IBD
New and Future Adhesion Molecule Based Therapies in IBD Brian G. Feagan Professor of Medicine, Epidemiology and Biostatistics University of Western Ontario Robarts Clinical Trials London, Ontario, Canada
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,
More informationCAG Symposium: Management of IBD in 2018
CAG Symposium: Management of IBD in 2018 Waqqas Afif, MD, M. Sc., FRCPC, Associate Professor, Department of Medicine Division of Gastroenterology McGill University Health Center X X X X X CanMEDS Roles
More informationAssociation Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease
Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease Jean Frédéric Colombel, William J. Sandborn, Matthieu Allez, Jean Louis Dupas, Olivier
More informationWHY HAVE WE NOT FINALLY FIGURED OUT COMBINATION THERAPY?
WHY HAVE WE NOT FINALLY FIGURED OUT COMBINATION THERAPY? Siew Ng, Professor MBBS, FRCP, (Lon, Edin), PhD (Lond), AGAF, FHKCP, FHKAM (medicine) Department of Medicine and Therapeutics Chinese University
More informationPosition of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy
Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy Stephen B. Hanauer, MD University of Chicago Potential Conflicts: Centocor/Schering, Abbott, UCB, Elan, Berlex, PDL Goals of Treatment
More informationReferring to Part of Dossier: Volume: Page:
Synopsis Abbott Laboratories Name of Study Drug: Adalimumab Name of Active Ingredient: Adalimumab Title of Study: Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority
More information5/2/2018 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD
5/2/218 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD Grant support for preclinical studies: Janssen, Gusto Global, Vedanta, Artizan BALFOUR SARTOR, MD DISTINGUISHED
More informationTumor necrosis factor-alpha antibody for maintenace of remission in Crohn s disease (Review)
Tumor necrosis factor-alpha antibody for maintenace of remission in Crohn s disease (Review) Behm BW, Bickston SJ This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration
More information4/16/2018. Updates in Crohn s Disease. Disclosures. Learning Objectives. Crohn s Disease is Progressive and Destructive
4/16/218 Disclosures Updates in Crohn s Disease David T. Rubin, MD Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition University of Chicago Consultant
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Assistant Professor of Clinical Pediatrics Division of Gastroenterology,
More informationModerately to severely active ulcerative colitis
Adalimumab in the Treatment of Moderate-to-Severe Ulcerative Colitis: ULTRA 2 Trial Results Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients
More informationPositioning New Therapies
Positioning New Therapies Stephen Hanauer, MD Professor of Medicine Medical Director, Digestive Disease Center Northwestern Medicine Chicago, Illinois Speaker Disclosure Stephen Hanauer, MD has disclosed
More informationJoin the conversation at #GIFORUMCCFA
1 Join the conversation at #GIFORUMCCFA 2 Disclosures In accordance with the ACCME Standards for Commercial Support of CME, the speakers for this course have been asked to disclose to participants the
More informationMedical Therapy for Pediatric IBD: Efficacy and Safety
Medical Therapy for Pediatric IBD: Efficacy and Safety Betsy Maxwell, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Pediatric IBD: Defining Remission
More informationImmunogenicity of Biologic Agents and How to Prevent Sensitization
Immunogenicity of Biologic Agents and How to Prevent Sensitization William J. Sandborn, MD Professor and Chief, Division of Gastroenterology Director, UCSD IBD Center La Jolla, California, USA Learning
More informationDDW abstract review: Crohn s disease/ibd. Jesse Siffledeen Edmonton. May 26-28, 2017 Fairmont Chateau Lake Louise, Lake Louise, Alberta
DDW abstract review: Crohn s disease/ibd Jesse Siffledeen Edmonton May 26-28, 2017 Fairmont Chateau Lake Louise, Lake Louise, Alberta Disclosure of Commercial Support Potential for conflict(s) of interest:
More informationustekinumab 130mg concentrate for solution for infusion and 90mg solution for injection (Stelara ) SMC No. (1250/17) Janssen-Cilag Ltd
ustekinumab 130mg concentrate for solution for infusion and 90mg solution for injection (Stelara ) SMC No. (1250/17) Janssen-Cilag Ltd 09 June 2017 The Scottish Medicines Consortium (SMC) has completed
More informationBeyond Anti TNFs: positioning of other biologics for Crohn s disease. Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center
Beyond Anti TNFs: positioning of other biologics for Crohn s disease Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center Objectives: To define high and low risk patient and disease features
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 October 2012 REMICADE 100 mg, powder for concentrate for solution for infusion B/1 vial (CIP code: 562 070-1) Applicant:
More informationPositioning Biologics in Ulcerative Colitis
Positioning Biologics in Ulcerative Colitis Bruce E. Sands, MD, MS Acting Chief, Gastrointestinal Unit Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Sequential Therapies
More informationExtrapolation & Pediatric Development: A case study from pediatric Ulcerative Colitis Richard Strauss, MD
Extrapolation & Pediatric Development: A case study from pediatric Ulcerative Colitis Richard Strauss, MD Immunology Clinical Development Janssen Research and Development Agenda Rationale for extrapolation
More informationJohn F. Valentine, MD Inflammatory Bowel Disease Program University of Utah
John F. Valentine, MD Inflammatory Bowel Disease Program University of Utah Hawaii 1/20/2017 DISCLOSURES Research Support: NIH, Pfizer, Celgene, AbbVie, Roche/Genentech, Takeda, CCFA OBJECTIVES Review
More informationWithdrawal of drug therapy in patients with quiescent Crohn s disease
Withdrawal of drug therapy in patients with quiescent Crohn s disease DR. JEAN-FRÉDÉRIC COLOMBEL DIRECTOR OF THE IBD CENTER, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NEW YORK, USA Withdrawal of drug therapy
More informationLong-term Efficacy of Vedolizumab for Crohn s Disease
Journal of Crohn's and Colitis, 217, 412 424 doi:1.193/ecco-jcc/jjw176 Advance Access publication September 28, 216 Original Article Original Article Long-term Efficacy of Vedolizumab for Crohn s Disease
More informationPersonalized Medicine in IBD
Personalized Medicine in IBD Anita Afzali MD, MPH Assistant Professor of Medicine Director, Inflammatory Bowel Diseases Program University of Washington Harborview Medical Center CCFA April 2 nd, 2016
More informationPharmacotherapy of Inflammatory Bowel Disorder
PHARMACY / MEDICAL POLICY 5.01.563 Pharmacotherapy of Inflammatory Bowel Disorder Effective Date: Feb. 14, 2018 Last Revised: April 1, 2018 Replaces: Extracted from 5.01.550 RELATED MEDICAL POLICIES: 11.01.523
More informationInflammatory bowel disease: Novel therpaies NZ November 2018
Inflammatory bowel disease: Novel therpaies NZ November 2018 Dr Charlie Lees Consultant Gastroenterologist From the Edinburgh IBD Unit at the Western General Hospital History of treatment for IBD 1950s
More informationPharmacotherapy of Inflammatory Bowel Disorder
PHARMACY / MEDICAL POLICY 5.01.563 Pharmacotherapy of Inflammatory Bowel Disorder Effective Date: May 1, 2018 Last Revised: April 18, 2018 Replaces: Extracted from 5.01.550 RELATED MEDICAL POLICIES: 11.01.523
More informationPharmacotherapy of Inflammatory Bowel Disorder
PHARMACY / MEDICAL POLICY 5.01.563 Pharmacotherapy of Inflammatory Bowel Disorder Effective Date: June 9, 2019* Last Revised: Feb. 12, 2019 Replaces: Extracted from 5.01.550 RELATED MEDICAL POLICIES: 11.01.523
More informationInitiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease
Initiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease The Case for Starting with Anti-TNFα Agents Maria Oliva-Hemker, M.D. Chief, Division of Pediatric Gastroenterology &
More informationOptimizing the effectiveness of anti-tnf therapy in paediatric IBD
Optimizing the effectiveness of anti-tnf therapy in paediatric IBD Anne Griffiths MD, FRCPC Co-Lead, Inflammatory Bowel Disease Center Northbridge Chair in IBD Hospital for Sick Children, Professor of
More informationAgenda. Predictive markers in IBD. Management of ulcerative colitis. Management of Crohn s disease
Agenda Predictive markers in IBD Management of ulcerative colitis Management of Crohn s disease 2 Patients With UC (%) Distribution of UC Disease Severity at Presentation 1 Fulminant disease (9%) 8 6 4
More informationPerianal and Fistulizing Crohn s Disease: Tough Management Decisions. Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic
Perianal and Fistulizing Crohn s Disease: Tough Management Decisions Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic Talk Overview Background Assessment and Classification
More informationPersonalized Medicine. Selecting the Right First-line Biologic Agent. Gene Expression Profiles Crohn s Disease. The Right Treatment
Personalized Medicine Selecting the Right First-line Biologic Agent William Tremaine, M.D. Maxine and Jack Zarrow Professor Mayo Clinic Rochester, MN, USA The Right Treatment Pretreatment Genomic Analysis
More informationFistulizing Crohn s Disease: The Aggressive Approach
Fistulizing Crohn s Disease: The Aggressive Approach Bruce E. Sands, MD, MS MGH Crohn s and Colitis Center and Gastrointestinal Unit Massachusetts General Hospital Boston, USA Case Presentation: Summary
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Brian Feagan, MD, FACG Professor of Medicine and Epidemiology and Biostatistics Director, Robarts Clinical Trials Robarts Research Institute University
More informationCommon Questions in Crohn s Disease Therapy. Case
Common Questions in Crohn s Disease Therapy Jean-Paul Achkar, MD, FACG Kenneth Rainin Chair for IBD Research Cleveland Clinic Case 23 yo male with 1 year history of diarrhea, abdominal pain and 15 pound
More informationThe Refractory Crohn s Disease
The Refractory Crohn s Disease Patient David T. Rubin, MD, FACG Professor of Medicine Co-Director, Inflammatory Bowel Disease Center Interim Chief, Section of Gastroenterology, Hepatology and Nutrition
More informationDrug Level Monitoring in IBD. Objectives
Drug Level Monitoring in IBD Corey A. Siegel, MD, MS Director, Dartmouth-Hitchcock IBD Center Associate Professor of Medicine, Geisel School of Medicine at Dartmouth Objectives Review non-biologic drug
More informationAdverse Events From Biologic Agents in IBD
Adverse Events From Biologic Agents in IBD David A. Schwartz, MD, FACG Director, Inflammatory Bowel Disease Center Professor of Medicine Vanderbilt University Medical Center Case Page 1 of 24 28 yo with
More informationTreatment Goals. Current Therapeutic Pyramids Crohn s Disease Ulcerative Colitis 11/14/10
Current Management of IBD: From Conventional Agents to Biologics Stephen B. Hanauer, M.D. University of Chicago Treatment Goals Induce and maintain response/ remission Prevent complications Improve quality
More informationOp#mal Therapy in IBD: Where Are We Now?
Op#mal Therapy in IBD: Where Are We Now? Brian G. Feagan MD Professor of Medicine, Epidemiology and Biosta;s;cs Western University Senior Scien;fic Director, Robarts Clinical Trials, London, Ontario, Canada
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Gary R. Lichtenstein, MD, FACG Professor of Medicine Director, Inflammatory Bowel Disease Program University of Pennsylvania Philadelphia, PA In my
More informationEvidence review for Surrey Prescribing Clinical Network SUMMARY
East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG, Surrey Heath CCG, Crawley CCG, Horsham & Mid-Sussex CCG Evidence review for Surrey Prescribing Clinical Network Medicine
More informationUlcerative colitis (UC) is a chronic inflammatory
Induction and Maintenance Therapy with Vedolizumab, a Novel Biologic Therapy for Ulcerative Colitis Feagan BG, Rutgeerts P, Sands BE, et al; GEMINI 1 Study Group. Vedolizumab as induction and maintenance
More information1. Comparative effectiveness of vedolizumab
Cost-effectiveness of vedolizumab (Entyvio ) for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were
More informationDr. Elmer Schabel, MD. Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany (No conflicts of interest)
EMA workshop on the development of new medicinal products for the treatment of ulcerative colitis and Crohn s disease Overview of authorised medicines for IBD in Europe - previous regulatory positions
More informationUlcerative Colitis Therapy. Faculty Disclosure. Acknowledgements 28/11/2013. Amy Morse November 30/13
Ulcerative Colitis Therapy Amy Morse November 30/13 GI for GP s Jasper AB Faculty Disclosure Faculty: Amy Morse Relationships with commercial interests: Grants/Research Support: Therapeutic Fellowship
More informationSynopsis (C0524T12 GO LIVE)
Protocol: EudraCT No.: 2005-003232-21 Title of the study: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFα Monoclonal Antibody, Administered Intravenously,
More informationSelective leucocyte trafficking inhibitors for treatment of IBD
Selective leucocyte trafficking inhibitors for treatment of IBD Séverine Vermeire MD, PhD Department of Gastroenterology University Hospitals Leuven Belgium Migration of Leucocytes plays a key role in
More informationPersonalized Medicine in IBD: Where Are We in 2013
Personalized Medicine in IBD: Where Are We in 2013 David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University Medical Center What is Personalized
More informationModern Management of Perianal Fistulas in Crohn s Disease (PFCD): Future Directions
Modern Management of Perianal Fistulas in Crohn s Disease (PFCD): Future Directions Rami Ismail, Pharm.D., BCPS, BCCCP, CACP Lead Clinical staff Pharmacist, Cleveland Clinic Abu Dhabi Disclosure Information
More informationTreating to Achieve a Target and Disease Monitoring in 2015: State of the Art
Treating to Achieve a Target and Disease Monitoring in 2015: State of the Art David T. Rubin, MD The Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition
More informationScottish Medicines Consortium
Scottish Medicines Consortium infliximab 100mg powder for intravenous infusion (Remicade ) No. (364/07) Schering-Plough UK Ltd 6 April 2007 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationIBD in teenagers Biological and Transition
IBD in teenagers Biological and Transition Dr Warren Hyer Consultant Paediatric Gastroenterologist St Mark s Hospital Chelsea and Westminster Hospital Conflict of Interest None to declare Fee for presentation
More informationDefinitions. Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency)
CROHN S DISEASE Definitions Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency) Recurrence: The reappearance of lesions after surgical resection Endoscopic remission:
More informationTRANSPARENCY COMMITTEE
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 19 February 2014 SIMPONI 50 mg, solution for injection in pre-filled pen Pre-filled B/1 pen - 0.5 ml (CIP: 34009 397
More informationNorthern Treatment Advisory Group. Biologic drugs for treatment-refractory moderately to severely active ulcerative colitis
Northern Treatment Advisory Group Biologic drugs for treatment-refractory moderately to severely active ulcerative colitis Lead author: Dominic McDermott Regional Drug & Therapeutics Centre (Newcastle)
More informationAnti-TNF and cyclosporine are identical choices for severe ulcerative colitis refractory to steroid therapy CON Peter Laszlo LAKATOS Semmelweis
Anti-TNF and cyclosporine are identical choices for severe ulcerative colitis refractory to steroid therapy CON Peter Laszlo LAKATOS Semmelweis University, 1st Department of Medicine Budapest June 13-15,
More informationIl ruolo degli anticorpi anti farmaco nella pratica clinica
Il ruolo degli anticorpi anti farmaco nella pratica clinica Daniela Pugliese, MD IBD Unit Complesso Integrato Columbus Gemelli Hospital Catholic University Foundation, Rome - Italy Therapeutic Drug monitoring
More informationHow to Optimize Induction and Maintenance Responses: Definitions and Dosing Advances in Inflammatory Bowel Disease December 6, 2009
How to Optimize Induction and Maintenance Responses: Definitions and Dosing 2009 Advances in Inflammatory Bowel Disease December 6, 2009 Fernando Velayos MD MPH University of California, San Francisco
More informationvedolizumab 300mg powder for concentrate for solution for infusion (Entyvio ) SMC No. (1064/15) Takeda UK Ltd
vedolizumab 300mg powder for concentrate for solution for infusion (Entyvio ) SMC No. (1064/15) Takeda UK Ltd 05 June 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationPRODUCT INFORMATION HUMIRA
NAME OF THE MEDICINE Adalimumab (rch) DESCRIPTION PRODUCT INFORMATION HUMIRA (adalimumab) is a recombinant human immunoglobulin (IgG1) monoclonal antibody containing only human peptide sequences. was created
More informationManaging Complications of IBD and Its Therapies David T. Rubin, MD, AGAF
Managing Complications of IBD and Its Therapies David T. Rubin, MD, AGAF Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition University of Chicago Medicine
More informationThe Best of IBD at UEGW (Crohn s)
The Best of IBD at UEGW (Crohn s) Iyad Issa MD Head of Gastroenterology, Rafik Hariri Univ Hosp Adjunct Faculty, School of Medicine, Leb Univ Founding Faculty, School Of Medicine, Leb Am Univ 1 The Best
More informationIncorporating Biologics Into Your Practice
Incorporating Biologics Into Your Practice Jeffrey M. Sobell MD Tufts University School of Medicine SkinCare Physicians Ora Clinical Research Disclosure Of Relationships With Industry Amgen AbbVie Celgene
More informationDavid Y. Graham, MD Baylor College of Medicine, Houston TX, USA
Phase III Randomized, Double Blind, Placebo- Controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Add-On Fixed-Dose Anti- Mycobacterial Therapy (RHB-104) in Moderately to
More informationEndpoints for Stopping Treatment in UC
Endpoints for Stopping Treatment in UC Jana G. Hashash, MD Assistant Professor of Medicine Inflammatory Bowel Disease Center Division of Gastroenterology, Hepatology, and Nutrition University of Pittsburgh
More information